Early versus late chest radiotherapy for limited stage small cell lung cancer.

PubWeight™: 1.17‹?› | Rank: Top 10%

🔗 View Article (PMID 15674960)

Published in Cochrane Database Syst Rev on January 25, 2005

Authors

M C G Pijls-Johannesma1, D De Ruysscher, P Lambin, I Rutten, J F Vansteenkiste

Author Affiliations

1: Radiation Oncology, Maastro-clinic, The Netherlands, H.Dunantstraat 5, Heerlen, Netherlands, 6419 PC. Madelon.pijls@maastro.nl

Articles citing this

Generating executable knowledge for evidence-based medicine using natural language and semantic processing. AMIA Annu Symp Proc (2006) 1.20

Treatment options for small cell lung cancer - do we have more choice? Br J Cancer (2010) 1.07

Limited-stage small cell lung cancer: current chemoradiotherapy treatment paradigms. Oncologist (2010) 1.02

Phase II study of accelerated high-dose radiotherapy with concurrent chemotherapy for patients with limited small-cell lung cancer: Radiation Therapy Oncology Group protocol 0239. Int J Radiat Oncol Biol Phys (2012) 0.98

Protocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status. BMJ Open (2016) 0.96

Small cell lung cancer: will recent progress lead to improved outcomes? Clin Cancer Res (2015) 0.94

Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. Br J Cancer (2008) 0.91

A phase II study of paclitaxel + etoposide + cisplatin + concurrent radiation therapy for previously untreated limited stage small cell lung cancer (E2596): a trial of the Eastern Cooperative Oncology Group. J Thorac Oncol (2009) 0.81

Do we have enough evidence to implement particle therapy as standard treatment in lung cancer? A systematic literature review. Oncologist (2010) 0.79

Feasibility of omitting clinical target volume for limited-disease small cell lung cancer treated with chemotherapy and intensity-modulated radiotherapy. Radiat Oncol (2014) 0.79

The start of chemotherapy until the end of radiotherapy in patients with limited-stage small cell lung cancer. Korean J Intern Med (2013) 0.78

Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. Ann Oncol (2016) 0.76

Evaluation of the role of remission status in a heterogeneous limited disease small-cell lung cancer patient cohort treated with definitive chemoradiotherapy. BMC Cancer (2016) 0.75

Investigating a Correlation between Chemoradiotherapy Schedule Parameters and Overall Survival in a real-life LD SCLC Patient Cohort. J Cancer (2016) 0.75

Radiation dose is associated with prognosis of small cell lung cancer with superior vena cava syndrome. Int J Clin Exp Med (2015) 0.75

Articles by these authors

ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J (2009) 3.08

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 2.31

Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer (1999) 2.22

Low-dose hypersensitivity: current status and possible mechanisms. Int J Radiat Oncol Biol Phys (2001) 2.14

Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann Oncol (2005) 1.96

Methods for the quantification of DNA double-strand breaks determined from the distribution of DNA fragment sizes measured by pulsed-field gel electrophoresis. Radiat Res (1995) 1.61

Camurati-Engelmann disease: a late and sporadic case with metaphyseal involvement. Eur Radiol (1999) 1.61

Reliability of molecular weight determination of proteins by polyacrylamide gradient gel electrophoresis in the presence of sodium dodecyl sulfate. Anal Biochem (1978) 1.57

Analysis of complications in a prospective randomized trial comparing two brachytherapy low dose rates in cervical carcinoma. Int J Radiat Oncol Biol Phys (1994) 1.51

Frequency and prognostic importance of thrombocytopenia in symptom-free HIV-infected individuals: a 5-year prospective study. AIDS (1991) 1.46

Is pulsed dose rate more damaging to spinal cord of rats than continuous low dose rate? Radiother Oncol (1997) 1.46

Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.46

The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol (2000) 1.26

Hypoxia as a target for combined modality treatments. Eur J Cancer (2002) 1.24

Hypersensitivity to very-low single radiation doses: its relationship to the adaptive response and induced radioresistance. Mutat Res (1996) 1.19

Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo. Br J Cancer (2006) 1.19

Robust prognostic value of a knowledge-based proliferation signature across large patient microarray studies spanning different cancer types. Br J Cancer (2008) 1.15

Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum. Cancer Gene Ther (2001) 1.12

Low dose hyper-radiosensitivity and increased radioresistance in mammalian cells. Int J Radiat Biol (1997) 1.11

Selective serum IgA deficiency. Frequency among 15,200 French blood donors. Vox Sang (1973) 1.10

Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. Ann Oncol (2008) 1.08

Comparison of Bayesian network and support vector machine models for two-year survival prediction in lung cancer patients treated with radiotherapy. Med Phys (2010) 1.06

Radio-responsive recA promoter significantly increases TNFalpha production in recombinant clostridia after 2 Gy irradiation. Gene Ther (2001) 1.05

Vascular targeting of solid tumours: a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas. Eur J Cancer (2000) 1.04

Frequency of monoclonal gammapathy ('M components') in 13,400 sera from blood donors. Vox Sang (1972) 1.04

Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas. FEMS Immunol Med Microbiol (2001) 1.04

Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development. Ann Oncol (2011) 1.03

Purification of the human serum inter-alpha-trypsin inhibitor by zinc chelate and hydrophobic interaction chromatographies. Anal Biochem (1980) 1.02

Syndrome of inappropriate antidiuretic hormone associated with chemotherapy-induced tumour lysis in small-cell lung cancer: case report and literature review. Ann Oncol (2000) 1.01

Tumor-specific gene delivery using genetically engineered bacteria. Curr Gene Ther (2003) 1.00

Tumoural perfusion as measured by dynamic computed tomography in head and neck carcinoma. Radiother Oncol (1999) 0.99

A new method for determination of molecular weights of proteins by electrophoresis across a sodium dodecyl sulfate (SDS)-polyacrylamide gradient gel. Anal Biochem (1976) 0.98

Molecular weight estimation of proteins by electrophoresis in linear polyacrylamide gradient gels in the absence of denaturing agents. Anal Biochem (1979) 0.98

Human monoclonal antibody against Rh(D) antigen: partial characterization of the Rh(D) polypeptide from human erythrocytes. Blood (1987) 0.97

Phased attenuation correction in respiration correlated computed tomography/positron emitted tomography. Med Phys (2006) 0.96

A fatal case of cholestatic liver failure probably related to gemcitabine. Ann Oncol (2000) 0.96

Maximal neutropenia during chemotherapy and radiotherapy is significantly associated with the development of acute radiation-induced dysphagia in lung cancer patients. Ann Oncol (2007) 0.96

Changes in the oxygenation of head and neck tumors during carbogen breathing. Radiother Oncol (1993) 0.95

Monoclonal gammopathies in asymptomatic HIV-seropositive patients. Clin Chem (1987) 0.93

Stable Escherichia coli-Clostridium acetobutylicum shuttle vector for secretion of murine tumor necrosis factor alpha. Appl Environ Microbiol (1999) 0.92

Impact of fatigue on overall quality of life in lung and breast cancer patients selected for high-dose radiotherapy. Ann Oncol (2007) 0.92

Potential role for low dose limited-field radiation therapy (2 x 2 grays) in advanced low-grade non-Hodgkin's lymphomas. Hematol Oncol (1994) 0.92

Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo-controlled multicenter study. J Clin Oncol (1996) 0.91

Flow cytometric monitoring of allergen induced basophil activation. Cytometry (1995) 0.91

Oxygenation of head and neck tumors. Cancer (1993) 0.90

Independent and functional validation of a multi-tumour-type proliferation signature. Br J Cancer (2012) 0.90

Malignant evolution of asymptomatic monoclonal IgM after seven and fifteen years in two siblings of a patient with Waldenström's macroglobulinemia. Acta Med Scand (1982) 0.90

Efficient isolation of total RNA from Clostridium without DNA contamination. J Microbiol Methods (2001) 0.90

Non-invasive 19F MR spectroscopy of 5-fluorocytosine to 5-fluorouracil conversion by recombinant Salmonella in tumours. Br J Cancer (2003) 0.90

The use of radiation-induced bacterial promoters in anaerobic conditions: a means to control gene expression in clostridium-mediated therapy for cancer. Radiat Res (2001) 0.90

Decreased DNA-PK activity in human cancer cells exhibiting hypersensitivity to low-dose irradiation. Br J Cancer (2000) 0.89

Heterotaxy syndrome in an adult, with polysplenia, visceral and cardiovascular malposition. JBR-BTR (2001) 0.89

Flow cytometric evaluation of human basophils. Cytometry (1993) 0.89

A global calibration model for a-Si EPIDs used for transit dosimetry. Med Phys (2007) 0.88

Non-invasive tumour perfusion measurement by dynamic CT: preliminary results. Radiother Oncol (1997) 0.87

Increasing specificity of anti-tumor therapy: cytotoxic protein delivery by non-pathogenic clostridia under regulation of radio-induced promoters. Anticancer Res (2001) 0.87

Adverse transfusion reactions associated with a precipitating anti-C4 antibody of anti-Rodgers specificity. Vox Sang (1984) 0.87

Therapy response assessment in radiotherapy of lung cancer. Q J Nucl Med Mol Imaging (2011) 0.86

Insertion or deletion of the Cheo box modifies radiation inducibility of Clostridium promoters. Appl Environ Microbiol (2001) 0.86

Prospective follow-up of monoclonal gammopathies in HIV-infected individuals. Br J Haematol (1993) 0.85

Purification and partial characterization of a hepatocyte antiproliferative glycopeptide. J Cell Biochem (1989) 0.85

Systematic survey of monoclonal gammapathies in the sera from blood donors. Transfusion (1979) 0.85

Isotypic analysis of grass pollen-specific immunoglobulins in human plasma. 1. Specialization of certain classes and subclasses in the immune response. Int Arch Allergy Immunol (1993) 0.84

The extracellular domain of the human erythropoietin receptor: expression as a fusion protein in Escherichia coli, purification, and biological properties. Prep Biochem Biotechnol (1999) 0.84

The utility of SPECT in determining the relationship between radiation dose and salivary gland dysfunction after radiotherapy. Nucl Med Commun (2001) 0.84

In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int J Radiat Oncol Biol Phys (2001) 0.84

Prediction of DVH parameter changes due to setup errors for breast cancer treatment based on 2D portal dosimetry. Med Phys (2009) 0.83

Broncholithiasis: rare but still present. Respir Med (1998) 0.83

Clostridium spores for tumor-specific drug delivery. Anticancer Drugs (2002) 0.83

Follow-up of subjects with isolated and persistent anti-core (anti-p24 or anti-p17) antibodies to HIV. AIDS (1988) 0.83

Verification of treatment parameter transfer by means of electronic portal dosimetry. Med Phys (2004) 0.83

Follow-up of monoclonal gammopathies in asymptomatic HIV-infected subjects. Clin Chem (1989) 0.82

Serum neopterin and beta 2-microglobulin concentrations in monoclonal gammopathies. Acta Med Scand (1988) 0.82

Lhermitte sign and myelopathy after irradiation of the cervical spinal cord in radiotherapy treatment of head and neck cancer. Strahlenther Onkol (2011) 0.82

BOLD contrast fMRI of whole rodent tumour during air or carbogen breathing using echo-planar imaging at 1.5 T. Eur Radiol (2001) 0.82

Isotypic analysis of grass-pollen-specific immunoglobulins in human plasma. 2. Quantification of the IgE, IgM, IgA class and the IgG subclass antibodies. Int Arch Allergy Immunol (1993) 0.82

Serum neopterin and beta 2-microglobulin in anti-HIV positive blood donors. Lancet (1986) 0.82

Rapid progression to AIDS in dual HIV-1/HTLV-I infection. Lancet (1990) 0.81

Does sucralfate reduce the acute side-effects in head and neck cancer treated with radiotherapy? A double-blind randomized trial. Radiother Oncol (1998) 0.81

Monoclonal IgD. A comparative study of 60 sera with IgD "M" component. Biomedicine (1974) 0.81

Selective deficit in antibodies specific for the superantigen binding site of gp120 in HIV infection. FASEB J (1998) 0.81

Local production of IgG and IgG subclasses in the aqueous humor of patients with Fuchs heterochromic cyclitis, herpetic uveitis and toxoplasmic chorioretinitis. Int Ophthalmol (1998) 0.81

Relocatable fixation systems in intracranial stereotactic radiotherapy. Accuracy of serial CT scans and patient acceptance in a randomized design. Strahlenther Onkol (2011) 0.81

Measurement of alloantibody by flow cytometry. J Immunol Methods (1990) 0.80

Adaptive response and induced resistance. C R Acad Sci III (1999) 0.80

Waldenström's macroglobulinemia in monozygotic twins. Acta Med Scand (1986) 0.80

Radiation-induced oesophagitis in lung cancer patients. Is susceptibility for neutropenia a risk factor? Strahlenther Onkol (2012) 0.80

Preparation and biological properties of monoclonal antibodies against human erythropoietin. Hybridoma (1993) 0.80

Selective alterations of the antibody response to HIV-1. Appl Biochem Biotechnol (1998) 0.80

Progression to AIDS in the majority of asymptomatic HIV-infected people. AIDS (1989) 0.80

Sedimentation rate as a predictive marker in HIV infection. AIDS (1988) 0.80

[Studies on human alpha-2 macroglobulin structure and its complexes with proteases, using polyacrylamide gel electrophoresis]. Rev Fr Transfus Immunohematol (1975) 0.80

IgG monoclonal gammapathy in the sister of a patient with Waldenström's macroglobulinaemia. Biomedicine (1973) 0.80

Current preclinical and clinical applications of hypoxia PET imaging using 2-nitroimidazoles. Q J Nucl Med Mol Imaging (2014) 0.79

Clostridium as a tumor-specific delivery system of therapeutic proteins. Cancer Detect Prev (2001) 0.79

Albumin Vanves: a new fast-moving variant of European origin. Hum Hered (1982) 0.79